John G Ullman & Associates Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 78.0% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,695 shares of the biopharmaceutical company’s stock after acquiring an additional 2,495 shares during the quarter. John G Ullman & Associates Inc.’s holdings in Gilead Sciences were worth $385,000 as of its most recent SEC filing.
Other large investors also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP lifted its holdings in shares of Gilead Sciences by 1.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 5,129,197 shares of the biopharmaceutical company’s stock worth $320,822,000 after purchasing an additional 51,905 shares during the period. Massey Quick Simon & CO. LLC lifted its holdings in shares of Gilead Sciences by 12.6% during the first quarter. Massey Quick Simon & CO. LLC now owns 2,344 shares of the biopharmaceutical company’s stock worth $152,000 after purchasing an additional 263 shares during the period. Meeder Asset Management Inc. lifted its holdings in shares of Gilead Sciences by 3.0% during the first quarter. Meeder Asset Management Inc. now owns 92,850 shares of the biopharmaceutical company’s stock worth $6,036,000 after purchasing an additional 2,671 shares during the period. DORCHESTER WEALTH MANAGEMENT Co lifted its holdings in shares of Gilead Sciences by 2.2% during the first quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 80,368 shares of the biopharmaceutical company’s stock worth $5,225,000 after purchasing an additional 1,739 shares during the period. Finally, Investors Asset Management of Georgia Inc. GA ADV lifted its holdings in shares of Gilead Sciences by 4.7% during the first quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 12,642 shares of the biopharmaceutical company’s stock worth $822,000 after purchasing an additional 565 shares during the period. 78.87% of the stock is currently owned by institutional investors and hedge funds.
Several equities research analysts recently weighed in on GILD shares. Wells Fargo & Co raised Gilead Sciences from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $68.00 to $88.00 in a report on Monday, July 15th. Mizuho set a $88.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Cantor Fitzgerald set a $88.00 target price on Gilead Sciences and gave the company a “buy” rating in a report on Monday, July 15th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, July 15th. Finally, JPMorgan Chase & Co. reissued a “buy” rating and issued a $85.00 target price on shares of Gilead Sciences in a report on Wednesday, July 31st. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $82.29.
Shares of GILD stock traded up $0.27 during mid-day trading on Friday, reaching $63.14. The stock had a trading volume of 6,967,500 shares, compared to its average volume of 6,297,219. Gilead Sciences, Inc. has a 12-month low of $60.32 and a 12-month high of $79.61. The company has a market cap of $79.62 billion, a P/E ratio of 10.27, a price-to-earnings-growth ratio of 2.98 and a beta of 1.16. The business has a 50-day simple moving average of $66.16 and a 200 day simple moving average of $65.90. The company has a current ratio of 3.76, a quick ratio of 3.67 and a debt-to-equity ratio of 1.13.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $1.82 earnings per share for the quarter, beating analysts’ consensus estimates of $1.68 by $0.14. Gilead Sciences had a return on equity of 37.12% and a net margin of 26.64%. The business had revenue of $5.69 billion during the quarter, compared to analysts’ expectations of $5.54 billion. During the same quarter last year, the business posted $1.91 earnings per share. The business’s revenue for the quarter was down 2.8% on a year-over-year basis. Research analysts anticipate that Gilead Sciences, Inc. will post 6.65 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 3.99%. The ex-dividend date of this dividend is Thursday, September 12th. Gilead Sciences’s dividend payout ratio is currently 40.98%.
About Gilead Sciences
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
See Also: Compound Annual Growth Rate (CAGR)
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.